Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction

Gene Therapy

Volumn 10, Issue 22, 2003, Pages 1917-1925

  Tiede, A ^a   Eder, M ^a   von Depka, M ^a   Battmer, K ^a   Luther, S ^a   Kiem, H P ^b   Ganser, A ^a   Scherr, M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Coagulation factor VIII; Hematopoietic stem cells; Hemophilia A; Lentiviral gene transfer; NOD SCID xenotransplantation

Indexed keywords

CD34 ANTIGEN; LENTIVIRUS VECTOR; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ANIMAL CELL; ARTICLE; BLOOD SAMPLING; BONE MARROW CELL; CELL DIFFERENTIATION; CELL POPULATION; CELL TYPE; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE; MEGAKARYOCYTE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; XENOTRANSPLANTATION;

ANIMALS; CELL LINE; FACTOR VIII; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HEMOPHILIA A; HUMANS; LENTIVIRUS; MICE; MICE, INBRED NOD; MICE, SCID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEM CELL TRANSPLANTATION; STEM CELLS; TRANSDUCTION, GENETIC; TRANSPLANTATION, HETEROLOGOUS;

ANIMALIA; LENTIVIRUS;

EID: 0141962306     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302093     Document Type: Article

References (49)

1. High KA. Gene transfer as an approach to treating hemophilia. Circ Res 2001; 88: 137-144.
2. Chuah MK, Collen D, VandenDriessche T. Gene therapy for hemophilia. J Gene Med 2001; 3: 3-20.
3. White II GC. Gene therapy in hemophilia: clinical trials update. Thromb Haemost 2001; 86: 172-177.
4. Connelly S et al. Complete short-term correction of canine hemophilia A by in vivo gene therapy. Blood 1996; 88: 3846-3853.
5. Connelly S et al. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood 1998; 91: 3273-3281.
6. Lipshutz GS et al. Short-term correction of factor VIII deficiency in a murine model of hemophilia A after delivery of adenovirus murine factor VIII in utero. Proc Natl Acad Sci USA 1999; 96: 13324-13329.
7. Balagué C et al. Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector. Blood 2000; 95: 820-828.
8. Sarkar R et al. Partial correction of murine hemophilia A with neo-antigenic murine factor VIII. Hum Gene Ther 2000; 11: 881-894.
9. Bristol JA et al. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion. Hum Gene Ther 2001; 12: 1651-1661.
10. Gallo-Penn AM et al. Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs. Blood 2001; 97: 107-113.
11. Chuah MK et al. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. Blood 2002; 101: 1734-1743.
12. Burton M et al. Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein. Proc Natl Acad Sci USA 1999; 96: 12725-12730.
13. Chao H, Mao L, Bruce AT, Walsh CE. Sustained expression of human factor VIII in mice using a parvovirus-based vector. Blood 2000; 95: 1594-1599.
14. Chao H, Walsh CE. Induction of tolerance to human factor VIII in mice. Blood 2001; 97: 3311-3312.
15. Chao H et al. Expression of human factor VIII by splicing between dimerized AAV vectors. Mol Ther 2002; 5: 716-722.
16. Andrews JL et al. Evaluation of the duration of human factor VIII expression in nonhuman primates after systemic delivery of an adenoviral vector. Hum Gene Ther 2002; 13: 1331-1336.
17. VandenDriessche T et al. Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice. Proc Natl Acad Sci USA 1999; 96: 10379-10384.
18. Park F, Ohashi K, Kay MA. Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver. Blood 2000; 96: 1173-1176.
19. Stein CS et al. In vivo treatment of hemophilia A and mucopolysaccharidosis type VII using nonprimate lentiviral vectors. Mol Ther 2001; 3: 850-856.
20. VandenDriessche T et al. Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood 2002; 100: 813-822.
21. Hoeben RC et al. Toward gene therapy for hemophilia A: long-term persistence of factor VIII-secreting fibroblasts after transplantation into immunodeficient mice. Hum Gene Ther 1993; 4: 179-186.
22. Dwarki VJ et al. Gene therapy for hemophilia A: production of therapeutic levels of human factor VIII in vivo in mice. Proc Natl Acad Sci USA 1995; 92: 1023-1027.
23. Roth DA et al. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med 2001; 344: 1735-1742.
24. Chuah MK et al. Bone marrow stromal cells as targets for gene therapy of hemophilia A. Hum Gene Ther 1998; 9: 353-365.
25. Chuah MK et al. Long-term persistence of human bone marrow stromal cells transduced with factor VIII-retroviral vectors and transient production of therapeutic levels of human factor VIII in nomnyeloablated inummodeficient mice. Hum Gene Ther 2000; 11: 729-738.
26. Hoeben RC et al. Toward gene therapy in haemophilia A: retrovirus-mediated transfer of a factor VIII gene into murine haematopoietic progenitor cells. Thromb Haemost 1992; 67: 341-345.
27. Evans GL, Morgan RA. Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A. Proc Natl Acad Sci USA 1998; 95: 5734-5739.
28. Hollestelle MJ et al. Tissue distribution of factor VIII gene expression in vivo - a closer look. Thromb Haemost 2001; 86: 855-861.
29. Uchida N et al. HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated G0/G1 human hematopoietic stem cells. Proc Natl Acad Sci USA 1998; 95: 11939-11944.
30. Miyoshi H et al. Transduction of human CD34+ cells that mediate long-term engraftment of NCOD/SCID mice by HIV vectors. Science 1999; 283: 682-686.
31. Evans JT, Kelly PF, O'Neill E, Garcia JV. Human cord blood CD34+CD38- cell transduction via lentivirus-based gene transfer vectors. Hum Gene Ther 1999; 10: 1479-1489.
32. Case SS et al. Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. Proc Natl Acad Sci USA 1999; 96: 2988-2993.
33. + NOD/SCID-repopulating cells. Blood 2002; 99: 709-712.
34. Zennou V et al. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 2000; 101: 173-185.
35. Sirven A et al. The human immunodeficiency virus type-1 central DNA flap is a crucial determinant for lentiviral vector nuclear import and gene transduction of human hematopoietic stem cells. Blood 2000; 96: 4103-4110.
36. Zennou V et al. The HIV-1 DNA flap stimulates HIV vector-mediated cell transduction in the brain. Nat Biotechnol 2001; 19: 446-450.
37. Park F, Kay MA. Modified HIV-1 based lentiviral vectors have an effect on viral transduction efficiency and gene expression in vitro and in vivo. Mol Ther 2001; 4: 164-173.
38. Chinnasamy D et al. Lentiviral-mediated gene transfer into human lymphocytes: role of HIV-1 accessory proteins. Blood 2000; 96: 1309-1316.
39. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045.
40. Brown BD, Lillicrap D. Dangerous liaisons: the role of 'danger' signals in the immune response to gene therapy. Blood 2002; 100: 1133-1140.
41. Heim DA et al. Introduction of a xenogeneic gene via hematopoietic stem cells leads to specific tolerance in a rhesus monkey model. Mol Ther 2000; 1: 533-544.
42. Kang E et al. In vivo persistence of retrovirally transduced murine long-term repopulating cells is not limited by expression of foreign gene products in the fully or minimally myeloablated setting. Hum Gene Ther 2001; 12: 1663-1672.
43. Cameron C et al. The canine factor VIII cDNA and 5′ flanking sequence. Thromb Haemost 1998; 79: 317-322.
44. Naldini L et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267.
45. Naldini L et al. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996; 93: 11382-11388.
46. Zufferey R et al. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871-875.
47. Scherr M et al. Quantitative determination of lentiviral vector particle numbers by real-time PCR. Biotechniques 2001; 31: 520-526.
48. Eder M et al. Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation. Leukemia 1999; 13: 1383-1389.
49. Schiedlmeier B et al. Quantitative assessment of retroviral transfer of the human multidrug resistance 1 gene to human mobilized peripheral blood progenitor cells engrafted in nonobese diabetic/severe combined immunodeficient mice. Blood 2000; 95: 1237-1248.